세계의 동물용 백신 시장(-2029년) : 유형별(돼지, 가금, 가축, 반려동물), 기술별(약독화, 불활화, 톡소이드), 투여 경로별(근육내, 피하, 경구), 최종사용자별(병원, 클리닉)

The veterinary vaccines market is projected to reach USD 13.33 billion by 2029, from USD 9.39 billion in 2024, at a CAGR of 6.1%." during the forecast period.

The growing awareness of animal health, along with the rising pet population and pet ownership, is driving the adoption of veterinary vaccines. Government initiatives aimed at improving animal health and the increasing uptake of pet insurance policies are also contributing to this trend. In major markets like North America and Europe, many pet owners are purchasing pet insurance due to the significant rise in pet care spending in recent years. Additionally, the focus on developing new and advanced vaccine products, combined with the growing adoption of veterinary vaccines in emerging economies, is expected to further support market growth. However, the high costs associated with vaccines may pose a challenge to the veterinary vaccines market's expansion.

"The livestock vaccines segment of veterinary vaccines market to register highest share during the forecast period."

Based on type, the livestock vaccines segment accounted for the largest share. As livestock animals are owned for the production of food, such as meat and dairy products. As global demand for animal derived food increases and livestock farming intensifies to meet the nutritional needs of an expanding population, there is a greater emphasis on maintaining animal health, preventing disease outbreaks, and improving productivity. Additionally, government regulations, rising awareness about animal health, and growing demand for safer, disease-free food products are driving the adoption of livestock vaccines, further contributing to their dominant share in the market.

"The intramuscular segment to capture the largest market share of veterinary vaccines market."

Based on route of administration, intramuscular vaccines hold a higher share in the veterinary vaccines market due to their effectiveness and widespread use. Compared to conventional methods of administration like subcutaneous or oral vaccines, this kind of vaccine is delivered directly into the muscle, enabling a faster and more powerful immune response. Because of their ability to produce long-lasting immunity, intramuscular vaccines are frequently used to treat a range of conditions, including bacterial, viral, and parasite infections. The increased market share of intramuscular vaccines is partly a result of their shown efficacy, simplicity of use, and veterinarians' inclination for this approach in both individual pet care and large-scale farming.

"Asia pacific accounted for the fastest growing region of the veterinary vaccines market by region."

The global veterinary vaccines market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is the fastest growing market for veterinary vaccines. The increased ownership of pets is a major factor driving the need for veterinary care and vaccinations, particularly in economies like China, India, and Japan. Pet owners are also being encouraged to invest in vaccinations as a result of the region's increasing awareness of animal health and preventative measures. Growing focus on livestock health, better veterinary facilities, and economic expansion all contribute significantly to the market's growth. Governments and organizations have backed animal health initiatives, and more consumers are looking for improved pet healthcare as disposable incomes rise. The Asia Pacific region is becoming a significant growth engine for the veterinary vaccines market due to this confluence of variables.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1-35%, Tier 2-40%, and Tier 3- 25%
• By Designation: Directors-25%, Managers-50% and Others-25%
• By Region: North America-35%, Europe-30%, Asia Pacific-15% and RoW-20%

The major players operating in the veterinary vaccines market market are Zoetis(US), Merck & Co, Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco (US), Virbac (France), Ceva (France), Phibro Animal Health Corporation (US), Hester Biosciences Limited (India), Neogen Corporation (US), HIPRA (Spain), Biogenesis Bago (Argentina), Tianjin Ringpu BioTechnology Co., Ltd. (China), China Animal Husbandry Industry Co., LTD. (China), Jinyu Bio-technology Co., Ltd. (China), and Vaxxinova International B.V.(Netherlands).

Research Coverage

This report studies the veterinary vaccines market based on type, disease, technology, route of administration and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:

• Analysis of Key divers (increased companion animal population and pet ownership, growing incidence of infectious disease, government initiatives to improve animal health), restraints (high cost associated with vaccines), Opportunities (emerging markets, technological advancement and developments) , Challenge (limited awareness and shortage of veterinarians, stringent regulatory requirements)
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the veterinary vaccines market
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the veterinary vaccines market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the veterinary vaccines market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & GEOGRAPHICAL SPREAD
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key secondary sources
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key primary sources
    • 2.1.2.2 Objectives of primary research
    • 2.1.2.3 Key data from primary sources
    • 2.1.2.4 Key industry insights
    • 2.1.2.5 Breakdown of primaries
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS)
  • 2.2.2 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS
  • 2.2.3 TOP-DOWN APPROACH
• 2.3 DATA TRIANGULATION
• 2.4 MARKET SHARE ANALYSIS
• 2.5 STUDY ASSUMPTIONS
• 2.6 RISK ASSESSMENT
• 2.7 RESEARCH LIMITATIONS
  • 2.7.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.7.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 VETERINARY VACCINES MARKET OVERVIEW
• 4.2 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TECHNOLOGY AND COUNTRY (2023)
• 4.3 VETERINARY VACCINES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rise in companion animal population and pet ownership
    • 5.2.1.2 Increasing incidence of infectious zoonotic diseases
    • 5.2.1.3 Favorable initiatives by government agencies and animal associations
    • 5.2.1.4 Growing demand for animal-derived food products
    • 5.2.1.5 Increased adoption of pet insurance and high animal health expenditure
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of vaccine development
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Technological advancements for veterinary vaccine development
    • 5.2.3.2 Untapped growth potential in emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Limited awareness about animal vaccines and shortage of trained veterinarians in low-income countries
    • 5.2.4.2 Stringent regulatory requirements for licensing veterinary vaccines
• 5.3 INDUSTRY TRENDS
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 Recombinant DNA technology
    • 5.4.1.2 mRNA-based vaccines
  • 5.4.2 COMPLEMENTARY TECHNOLOGIES
    • 5.4.2.1 Vaccine adjuvant technology
    • 5.4.2.2 Needle-free and microneedle technology
  • 5.4.3 ADJACENT TECHNOLOGIES
    • 5.4.3.1 Genome editing technology
• 5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 VALUE CHAIN ANALYSIS
• 5.8 TRADE ANALYSIS
  • 5.8.1 IMPORT DATA FOR HS CODE 300242
  • 5.8.2 EXPORT DATA FOR HS CODE 300230
• 5.9 PORTER'S FIVE FORCES ANALYSIS
  • 5.9.1 THREAT OF NEW ENTRANTS
  • 5.9.2 THREAT OF SUBSTITUTES
  • 5.9.3 BARGAINING POWER OF SUPPLIERS
  • 5.9.4 BARGAINING POWER OF BUYERS
  • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.10 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.10.2 KEY BUYING CRITERIA
• 5.11 REGULATORY ANALYSIS
  • 5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.11.2 REGULATORY FRAMEWORK
    • 5.11.2.1 North America
      • 5.11.2.1.1 US
    • 5.11.2.2 Europe
    • 5.11.2.3 Rest of the World
      • 5.11.2.3.1 China
      • 5.11.2.3.2 Brazil
      • 5.11.2.3.3 Australia
• 5.12 PATENT ANALYSIS
  • 5.12.1 JURISDICTION AND TOP APPLICANT ANALYSIS
• 5.13 PRICING ANALYSIS
  • 5.13.1 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY KEY PLAYER, 2021-2023
  • 5.13.2 AVERAGE SELLING PRICE TREND, BY REGION, 2021-2023
• 5.14 KEY CONFERENCES & EVENTS, 2024-2026
• 5.15 ECOSYSTEM ANALYSIS
• 5.16 CASE STUDY ANALYSIS
• 5.17 REIMBURSEMENT ANALYSIS
• 5.18 UNMET NEEDS/END-USER EXPECTATIONS
• 5.19 IMPACT OF AI/GEN AI ON VETERINARY VACCINES MARKET
• 5.20 INVESTMENT & FUNDING SCENARIO
• 5.21 PIPELINE ANALYSIS

6 VETERINARY VACCINES MARKET, BY TYPE

• 6.1 INTRODUCTION
• 6.2 LIVESTOCK VACCINES
  • 6.2.1 BOVINE VACCINES
    • 6.2.1.1 Increasing demand for meat and milk to drive market
  • 6.2.2 SMALL RUMINANT VACCINES
    • 6.2.2.1 Increased livestock population and favorable government initiatives to propel market growth
• 6.3 PORCINE VACCINES
  • 6.3.1 GROWING AWARENESS ABOUT ANIMAL VACCINATION TO SUPPORT MARKET GROWTH
• 6.4 POULTRY VACCINES
  • 6.4.1 HIGH NEED FOR PROTEIN IN DAILY DIET TO AUGMENT MARKET GROWTH
• 6.5 COMPANION ANIMAL VACCINES
  • 6.5.1 CANINE VACCINES
    • 6.5.1.1 Increasing number of pet dogs and growing prevalence of zoonotic diseases to spur market growth
  • 6.5.2 FELINE VACCINES
    • 6.5.2.1 Rising adoption of cats and growing need for better veterinary care to boost market growth
• 6.6 AQUACULTURE VACCINES
  • 6.6.1 INCREASED POPULARITY OF COMMERCIAL FISH FARMING TO FUEL MARKET GROWTH
• 6.7 OTHER VETERINARY VACCINES

7 VETERINARY VACCINES MARKET, BY DISEASE

• 7.1 INTRODUCTION
• 7.2 LIVESTOCK DISEASES
  • 7.2.1 BOVINE DISEASES
    • 7.2.1.1 Favorable government programs and increased awareness about animal health in emerging economies to aid market growth
  • 7.2.2 SMALL RUMINANT DISEASES
    • 7.2.2.1 New vaccine formulations and improved delivery methods to propel vaccine demand for small ruminants
• 7.3 PORCINE DISEASES
  • 7.3.1 INCREASED FOCUS ON LARGE-SCALE INDUSTRIAL BREEDING OF PIGS TO AID MARKET GROWTH
• 7.4 POULTRY DISEASES
  • 7.4.1 ONGOING RISK OF AVIAN INFLUENZA OUTBREAKS TO SPUR NEED FOR POULTRY VACCINES
• 7.5 COMPANION ANIMAL DISEASES
  • 7.5.1 CANINE DISEASES
    • 7.5.1.1 Rise in pet ownership in emerging economies to boost market growth
  • 7.5.2 FELINE DISEASES
    • 7.5.2.1 Rise in cat population in urban areas to drive demand for feline disease management programs
• 7.6 AQUACULTURE DISEASES
  • 7.6.1 NEED FOR PREVENTIVE HEALTHCARE AND BIOSECURITY TO SUPPORT MARKET GROWTH
• 7.7 OTHER VETERINARY DISEASES

8 VETERINARY VACCINES MARKET, BY TECHNOLOGY

• 8.1 INTRODUCTION
• 8.2 LIVE ATTENUATED VACCINES
  • 8.2.1 EASE OF ADMINISTRATION AND LONG-TERM IMMUNITY TO SUPPORT MARKET GROWTH
• 8.3 INACTIVATED VACCINES
  • 8.3.1 NEED TO DEVELOP ARTIFICIAL IMMUNITY FROM NON-LIVING PATHOGENS TO DRIVE MARKET
• 8.4 TOXOID VACCINES
  • 8.4.1 TOXOID VACCINES TO STIMULATE IMMUNE SYSTEM AND PROTECT ANIMALS FROM BACTERIAL TOXINS
• 8.5 RECOMBINANT VACCINES
  • 8.5.1 BETTER STABILITY, HIGHER SAFETY, AND NO POST-VACCINATION REACTIONS TO SUPPORT VACCINE ADOPTION
• 8.6 OTHER VACCINE TECHNOLOGIES

9 VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION

• 9.1 INTRODUCTION
• 9.2 SUBCUTANEOUS ROUTE OF ADMINISTRATION
  • 9.2.1 EASE OF ADMINISTRATION, REDUCED PAIN, AND LOWER RISK OF TISSUE DAMAGE TO AID MARKET GROWTH
• 9.3 INTRAMUSCULAR ROUTE OF ADMINISTRATION
  • 9.3.1 BETTER IMMUNE RESPONSE AND LOWER RATE OF INJECTION-SITE REACTIONS TO AUGMENT MARKET GROWTH
• 9.4 ORAL ROUTE OF ADMINISTRATION
  • 9.4.1 COST-EFFECTIVENESS, INCREASED SAFETY, AND HIGH PATIENT ACCEPTABILITY TO SUPPORT MARKET GROWTH
• 9.5 INTRANASAL/SPRAY ROUTE OF ADMINISTRATION
  • 9.5.1 COST-EFFECTIVENESS AND RAPID ABSORPTION OF MEDICINE TO AID IN MASS VACCINATION
• 9.6 INTRAOCULAR ROUTE OF ADMINISTRATION
  • 9.6.1 SIMPLE ADMINISTRATION OF VACCINES IN LARGE-SCALE FARMING OPERATIONS TO AID MARKET GROWTH
• 9.7 OTHER ROUTES OF ADMINISTRATION

10 VETERINARY VACCINES MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 VETERINARY HOSPITALS
  • 10.2.1 GROWING AWARENESS ABOUT ANIMAL HEALTH AND INCREASING VETERINARY EXPENDITURE BY PET OWNERS TO DRIVE MARKET
• 10.3 VETERINARY CLINICS
  • 10.3.1 RISING NUMBER OF PET VISITS TO PRIVATE CLINICS TO SPUR MARKET GROWTH
• 10.4 OTHER END USERS

11 VETERINARY VACCINES MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 ASIA PACIFIC
  • 11.2.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.2.2 CHINA
    • 11.2.2.1 Increasing companion animal population and growing incidence of zoonotic diseases to drive market
  • 11.2.3 JAPAN
    • 11.2.3.1 High consumption of animal-derived products and increased pet health expenditure to propel market growth
  • 11.2.4 INDIA
    • 11.2.4.1 Growth in poultry industry and high demand for dairy products to augment market growth
  • 11.2.5 AUSTRALIA
    • 11.2.5.1 Increase in per capita income and rise in meat consumption to aid market growth
  • 11.2.6 SOUTH KOREA
    • 11.2.6.1 High demand for animal protein and favorable government subsidies for meat production to spur market growth
  • 11.2.7 NEW ZEALAND
    • 11.2.7.1 Favorable government initiatives and increased incidence of livestock diseases to boost market growth
  • 11.2.8 REST OF ASIA PACIFIC
• 11.3 NORTH AMERICA
  • 11.3.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.3.2 US
    • 11.3.2.1 US to dominate North American veterinary vaccines market during forecast period
  • 11.3.3 CANADA
    • 11.3.3.1 Rising pet ownership and increasing chicken consumption to drive demand for veterinary vaccines
• 11.4 EUROPE
  • 11.4.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.4.2 GERMANY
    • 11.4.2.1 Increased poultry consumption and high pet healthcare expenditure to drive market
  • 11.4.3 UK
    • 11.4.3.1 Rising adoption of pets to augment market growth
  • 11.4.4 FRANCE
    • 11.4.4.1 Rising companion animal and livestock population to boost market growth
  • 11.4.5 ITALY
    • 11.4.5.1 Better availability of pet products through large-scale outlets to augment market growth
  • 11.4.6 SPAIN
    • 11.4.6.1 Increase in veterinary practices and willingness to spend on animal healthcare to drive market
  • 11.4.7 NETHERLANDS
    • 11.4.7.1 High demand for meat and increased pressure on sustainable farming practices to fuel market growth
  • 11.4.8 REST OF EUROPE
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Well-established livestock industry to promote market growth
  • 11.5.3 MEXICO
    • 11.5.3.1 Focus on pork and poultry meat production to fuel market growth
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Kingdom of Saudi Arabia
      • 11.6.2.1.1 Favorable government initiatives for better animal health infrastructure to propel market growth
    • 11.6.2.2 UAE
      • 11.6.2.2.1 Favorable government initiatives to safeguard national livestock population and support sustainable agriculture
    • 11.6.2.3 Rest of GCC countries
  • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
• 12.3 REVENUE ANALYSIS, 2019-2023
• 12.4 MARKET SHARE ANALYSIS, 2023
  • 12.4.1 RANKING OF KEY MARKET PLAYERS, 2O23
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Region footprint
    • 12.5.5.3 Type footprint
    • 12.5.5.4 Disease footprint
    • 12.5.5.5 Technology footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 12.7 BRAND/PRODUCT COMPARISON
• 12.8 R&D EXPENDITURE OF KEY PLAYERS
• 12.9 COMPANY VALUATION & FINANCIAL METRICS
  • 12.9.1 FINANCIAL METRICS
  • 12.9.2 COMPANY VALUATION
• 12.10 COMPETITIVE SCENARIO
  • 12.10.1 PRODUCT LAUNCHES & APPROVALS
  • 12.10.2 DEALS
  • 12.10.3 EXPANSIONS
  • 12.10.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 MERCK & CO., INC.
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product launches & approvals
      • 13.1.1.3.2 Deals
      • 13.1.1.3.3 Expansions
      • 13.1.1.3.4 Other developments
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Right to win
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 ZOETIS
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product launches
      • 13.1.2.3.2 Deals
      • 13.1.2.3.3 Expansions
      • 13.1.2.3.4 Other developments
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Right to win
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product launches
      • 13.1.3.3.2 Expansions
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Right to win
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 ELANCO
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Deals
  • 13.1.5 CEVA
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Deals
      • 13.1.5.3.2 Expansions
  • 13.1.6 VIRBAC
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product launches
      • 13.1.6.3.2 Deals
      • 13.1.6.3.3 Expansions
      • 13.1.6.3.4 Other developments
  • 13.1.7 PHIBRO ANIMAL HEALTH CORPORATION
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
  • 13.1.8 HESTER BIOSCIENCES LIMITED
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Deals
  • 13.1.9 NEOGEN CORPORATION
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Deals
  • 13.1.10 HIPRA
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Product launches
  • 13.1.11 BIOGENESIS BAGO
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Expansions
  • 13.1.12 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Deals
  • 13.1.13 CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
  • 13.1.14 JINYU BIO-TECHNOLOGY CO., LTD.
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
    • 13.1.14.3 Recent developments
      • 13.1.14.3.1 Product approvals
  • 13.1.15 VAXXINOVA INTERNATIONAL B.V.
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Product approvals
      • 13.1.15.3.2 Expansions
• 13.2 OTHER COMPANIES
  • 13.2.1 ENDOVAC ANIMAL HEALTH
  • 13.2.2 BRILLIANT BIO PHARMA
  • 13.2.3 APTIMMUNE
  • 13.2.4 INDIAN IMMUNOLOGICALS LTD.
  • 13.2.5 TORIGEN PHARMACEUTICALS INC.
  • 13.2.6 INTAS PHARMACEUTICALS LTD.
  • 13.2.7 OUROFINO ANIMAL HEALTH
  • 13.2.8 BIOVAC LTD.
  • 13.2.9 LABORATOIRE LCV
  • 13.2.10 KYORITSU SEIYAKU CORPORATION

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS